Advertiser / Brand
Kenvue vs Revolution Beauty
Structured technology and market comparison · 2026
Direct Feature Comparison
Kenvue · vs · Revolution BeautyPublic consumer health brand owner spun out from Johnson & Johnson.
Public beauty brand selling makeup, skincare and haircare products.
Analyze all overlapping signals and tech stacks for Kenvue and Revolution Beauty
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Kenvue and Revolution Beauty?
When comparing Kenvue and Revolution Beauty, both platforms operate within the Advertiser / Brand ecosystem. Kenvue is positioned as Public consumer health brand owner spun out from Johnson & Johnson, whereas Revolution Beauty focuses on Public beauty brand selling makeup, skincare and haircare products. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Kenvue and Revolution Beauty?
When evaluating Kenvue and Revolution Beauty, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Kenvue and Revolution Beauty compare?
Kenvue is headquartered in United States (founded in 2023) with >5,000 employees. Revolution Beauty is based in United Kingdom (founded in 2014) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Kenvue vs Revolution Beauty
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Kenvue
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kenvue (2026-11-04)
On November 4, 2026, Kenvue LLC (as successor in interest to Kenvue Inc.) announced the settlement of exchange offers and consent solicitations conducted by Kimberly-Clark Corporation. Kimberly-Clark exchanged up to $7.0 billion aggregate principal amount of newly issued notes and cash for outstanding Kenvue senior notes across seven series maturing between 2028 and 2063. In total, approximately $6.38 billion aggregate principal amount of Kenvue Notes were validly tendered, accepted, and retired, leaving approximately $624.0 million outstanding across the seven series. Concurrent with the exchange, the Kenvue Third Supplemental Indenture became operative, substantially eliminating restrictive covenants, certain events of default, SEC reporting obligations, and merger/asset transfer restrictions under the Kenvue Indenture. Additionally, following an NYSE Form 25-NSE filing on November 2, 2026, Kenvue's common stock will be formally delisted on November 12, 2026, marking the post-acquisition integration of Kenvue under Kimberly-Clark.
- Kimberly-Clark accepted and cancelled $6,376,039,000 aggregate principal amount of Kenvue Notes across seven tranches, leaving $623,961,000 outstanding.
- The Third Supplemental Indenture stripped the Kenvue Indenture of substantially all restrictive covenants, SEC reporting requirements, and merger/asset transfer limits.
- Following an NYSE Form 25-NSE filing on November 2, 2026, Kenvue's Common Stock will be delisted from the New York Stock Exchange effective November 12, 2026.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kenvue (2026-11-02)
On November 2, 2026, Kenvue Inc. completed its merger with Kimberly-Clark Corporation (K-C), becoming a direct, wholly owned subsidiary named Kenvue LLC. Under the terms of the merger agreement, each share of Kenvue common stock was converted into the right to receive 0.14625 shares of K-C common stock plus $3.50 in cash. In connection with the closing, Kenvue terminated its $4.0 billion revolving credit agreement with JPMorgan Chase Bank, N.A., under which no borrowings were outstanding. Kenvue's entire 12-member board of directors resigned, and common stock was requested to be delisted from the New York Stock Exchange. Additionally, Kenvue LLC entered into a Fourth Supplemental Indenture assuming all obligations under seven tranches of outstanding senior notes aggregating $7.0 billion.
- Kenvue common stock converted into 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash per share, resulting in the delisting of KVUE from the NYSE.
- Kenvue terminated its $4.0 billion senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., having zero borrowings outstanding at closing.
- Kenvue LLC formally assumed obligations on $7.0 billion in total aggregate principal across seven series of outstanding senior notes due between 2028 and 2063.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kenvue (2026-10-30)
Kenvue Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on October 30, 2026, announcing its financial results for the fiscal third quarter ended September 27, 2026. The full quarterly financial release was furnished as Exhibit 99.1. The filing serves as the formal SEC disclosure vehicle for the company's third-quarter earnings release, signed by Interim Chief Financial Officer and Chief Accounting Officer Heather Howlett.
- Kenvue furnished its fiscal third-quarter financial results for the period ended September 27, 2026 via Exhibit 99.1 on October 30, 2026.
- The filing is furnished pursuant to Item 2.02 and is not deemed filed under Section 18 of the Securities Exchange Act of 1934.
- The Form 8-K was executed by Heather Howlett in her capacity as Interim Chief Financial Officer and Chief Accounting Officer.
Revolution Beauty
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)
On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.
- CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
- Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
- Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Kenvue and Revolution Beauty share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks